ANCA-Associated Vasculitis following the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Georges El Hasbani; Imad Uthman

doi:10.1159/000525562

ANCA-Associated Vasculitis following the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Nephron. 2023;147(2):103-107. doi: 10.1159/000525562. Epub 2022 Jul 18.

Authors

Georges El Hasbani¹, Imad Uthman²

Affiliations

¹ Department of Internal Medicine, St. Vincent's Medical Center, Bridgeport, Connecticut, USA, george.hasbany@lau.edu.
² Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Abstract

Coronavirus disease (COVID-19) vaccine can alter the body's immunological balance leading to autoimmune disease in rare cases. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of the autoimmune diseases which have been rarely reported to appear post-COVID-19 vaccine. Herein, we report the case of a 47-year-old woman who developed acute renal failure few days after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. Corticosteroids along with azathioprine were used for the management.

Keywords: ANCA-associated vasculitis; Acute renal failure; Autoimmunity; Coronavirus disease.

Publication types

Case Reports

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / etiology
Azathioprine
BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Female
Humans
Middle Aged

Substances

BNT162 Vaccine
COVID-19 Vaccines
Azathioprine

Grants and funding

The authors have received no funds to publish this report.